Form D · Pharmaceuticals
GENERICO, LLC
St. Louis, MO · CIK 0001577221
Offering snapshot reported Jul 29, 2015 · SEC filing
- Reported sold
- $3.76M Offering amount: $6.26M
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- $1 Reported outside-investor minimum
- First sale
- Jul 28, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 29, 2015 | Initial | $3,759,532 | No comparison | 21 | SEC filing |
| May 21, 2013 | Initial | $435,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-244621
Source: Form D, filed Jul 29, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dan Broderick | Director |
| Thomas Brya | Director, Executive |
| Michael Grimshaw | Director, Executive |
| Philip Vogt | Director, Executive |
| Shu Zhu | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
4041 Forest Park Ave.
St. Louis, MO, 63108
St. Louis, MO, 63108